SCHEMBL1744628

SCHEMBL1744628

O=[N+]([O-])c1ccc2c(c1)NC(=S)C(F)(F)O2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB8 P28062 1/20 0.39
ALPL P05186 1/20 0.39
CAPN9 O14815 1/20 0.38
CASP3 P42574 1/20 0.38
MAPT P10636 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 3/20 0.37
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP3A4 P08684 2/20 0.37
TDP1 Q9NUW8 1/20 0.37
PGR P06401 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CHRM1 P11229 1/20 0.36
HIF1A Q16665 1/20 0.36
SNCA P37840 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715441 0.84 ALPL (0.48) ALPLCAPN9CASP3MAPTMEN1
SCHEMBL1744525 0.84 PGR (0.43) PSMB8ALPLCAPN9CASP3MAPT
SCHEMBL13253434 0.79 ALPL (0.39) PSMB8ALPLCAPN9CASP3MAPT
SCHEMBL9174873 0.74 AKR1B1 (0.47) ALPLMAPTMEN1KMT2AALDH1A1
SCHEMBL56146 0.73 ALDH1A1 (0.51) ALPLCAPN9CASP3MAPTMEN1
SCHEMBL2627043 0.73 MAPT (0.46) PSMB8CAPN9CASP3MAPTMEN1
SCHEMBL3039804 0.72 ALPL (0.48) ALPLCAPN9CASP3MAPTMEN1
SCHEMBL8799897 0.71 ALPL (0.45) ALPLCAPN9CASP3MAPTMEN1
SCHEMBL15322146 0.71 PGR (0.34) PSMB8ALPLMAPTMEN1KMT2A
SCHEMBL13007730 0.71 ALPL (0.47) ALPLCAPN9CASP3MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9453028-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2016-09-27 US disclosed
US-9453028-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2016-09-27 US disclosed
US-9453028-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2016-09-27 US disclosed
US-20150376203-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2015-12-31 US disclosed
US-20150376203-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2015-12-31 US disclosed
US-20150376203-A1 Protein Kinase C Inhibitors and Uses Thereof MIDCAP FINANCIAL TRUST 2015-12-31 US disclosed
EP-2387572-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2015-09-16 EP disclosed
EP-2387572-B1 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS INC (US) 2015-09-16 EP disclosed
US-9095593-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-9095593-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS, INC. (US) 2015-08-04 US disclosed
US-8394951-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS INC. (US) 2013-03-12 US disclosed
US-8394951-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS INC. (US) 2013-03-12 US disclosed
US-8394951-B2 Protein kinase C inhibitors and uses thereof RIGEL PHARMACEUTICALS INC. (US) 2013-03-12 US disclosed
EP-2387572-A2 PROTEIN KINASE C INHIBITORS AND USES THEREOF Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040334-B2 Method of driving display device 02MICRO INTERNATIONAL LIMITED (KY) 2011-10-18 US disclosed
WO-2010083207-A2 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO disclosed
WO-2010083207-A2 PROTEIN KINASE C INHIBITORS AND USES THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO disclosed
US-20100184755-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2010-07-22 US disclosed
US-20100184755-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2010-07-22 US disclosed
US-20100184755-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF MIDCAP FINANCIAL TRUST 2010-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376203-A1 Protein Kinase C Inhibitors and Uses Thereof PRKCH, PRKCA, PRKCB PSMB8 2744/4885ALPL 2419/4885CAPN9 920/4885
US-20100184755-A1 PROTEIN KINASE C INHIBITORS AND USES THEREOF PRKCH, PRKCA, PRKCB PSMB8 2744/4885ALPL 2419/4885CAPN9 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.